Osteoporosis model rats show improved healing with FGF-2 treatment

NewsGuard 100/100 Score

A study investigating the effects of local application of fibroblast growth factor (FGF-2) on periodontal healing in osteoporosis model rats was presented at the 102nd General Session of the IADR, which was held in conjunction with the 53rd Annual Meeting of the American Association for Dental, Oral, and Craniofacial Research and the 48th Annual Meeting of the Canadian Association for Dental Research, on March 13-16, 2024, in New Orleans, LA, USA. 

The abstract, "FGF-2 Promotes Periodontal Healing in an Osteoporosis Model Rat" was presented during the "Periodontal Treatment Effects and Implant Therapy" Poster Session that took place on Thursday, March 14, 2024 at 3:45 p.m. Central Standard Time (UTC-6). 

The study, by Shinta Mori of Tokyo Dental College, Japan, assigned Wistar rats to an ovariectomy (OVX) -induced osteoporosis group or control group. The control group underwent a sham operation. At 8 weeks post-OVX, trabecular bone structure of the femur was analyzed to confirm the osteoporotic condition. Subsequently, standardized periodontal defects were surgically created in maxilla. The defects in each group received FGF-2 or left untreated. At 2 weeks post-periodontal surgery, we evaluated periodontal healing through histological observations (H-E staining) and micro-CT analysis.

By analyzing of the trabecular bone structure in the femur, we confirmed the osteoporotic condition. In histological analysis of periodontal healing at two weeks post-surgery, FGF-2-treated defects showed a greater level of newly formed bone compared with non-treated defects, in both OVX and control groups. At two weeks, bone volume fraction of FGF-2-treated defects (OVX ; 16.3 ± 5.0%, control ; 20.5 ± 4.2%) was significantly greater than non-treated defects (10.2 ± 3.6%, 13.7 ± 5.1%) (p < 0.001). Similarly, trabecular number of FGF-2 treated defects (OVX ; 2.0 ± 0.4 /mm, control ; 2.2 ± 0.2 /mm) was significantly greater than non-treated defects (1.4 ± 0.4 /mm, 1.7 ± 0.5 /mm) (p < 0.01).

The application of FGF-2 resulted in increased bone volume fraction, trabecular number, and formation of newly formed bone in the defects of OVX and control groups at 2 weeks. Within the limitation of short-term observation, FGF-2 seems to enhance periodontal healing, even under osteoporotic condition. 


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study reveals optimal drug sequencing for postmenopausal osteoporosis treatment